Skip to main content
. 2022 Jan 12;7(3):2533–2553. doi: 10.1021/acsomega.1c06603

Figure 3.

Figure 3

(a) Gadovist. (b) Magnevist. (c) Dotarem. (d) Multihance. (e) Dipentast. (f) Gd-DO3A-BTA (modified Gd-chelate). (g) Prohance. Gd-chelates in (a), (b), (c), (d), and (g) are clinically approved.